Solara Active Pharma Sciences Q1 Results FY27: Date, Revenue Estimates and What to Expect

June 26, 2026
Posted by: Kunal Singla
Category: News

Solara Active Pharma Sciences Q1 Results FY27 expected July-August 2026. Revenue estimate Rs.266-300 Cr.

Get Free Investment Predictions and Solara Active Pharma Sciences Research at Univest

Solara Active Pharma Sciences is expected to announce its Q1 FY27 (April to June 2026) financial results in July or August 2026. This Solara Active Pharma Sciences Q1 Results FY27 preview covers revenue prediction, Q1 expectations, key catalysts and risks, technical levels and the 12-month analyst price target.

India’s pharmaceutical and healthcare sector is navigating growth opportunities heading into Q1 Results FY27. The Solara Active Pharma Sciences Q1 Results FY27 Q1 prediction and Q1 expectations will reflect these sector dynamics.

This Solara Active Pharma Sciences Q1 Results FY27 Q1 result preview covers Q1 FY27 estimates, Q1 FY26 actual performance for context, key catalysts and risks, and the 12-month analyst price target.

Table of Contents

About Solara Active Pharma Sciences

Solara Active Pharma Sciences Q1 Results FY27 will be a critical Q1 result preview for investors. Solara Active Pharma Sciences is a pharmaceutical and healthcare company listed on the National Stock Exchange and Bombay Stock Exchange. Q1 FY27 (April to June 2026) results will be a key data point for assessing the full-year FY27 earnings trajectory. Any material beat or miss in the Solara Active Pharma Sciences Q1 Results FY27 Q1 result preview will likely drive meaningful stock price movement.

Solara Active Pharma Sciences reported Revenue of Rs.319 Cr in Q1 FY26, forming the year-on-year comparison base for the Solara Active Pharma Sciences Q1 Results FY27 estimate. The Solara Active Pharma Sciences Q1 Results FY27 Q1 expectations point to revenue of Rs.266-300 Cr.

Solara Active Pharma Sciences Q1 FY27 Estimates: What to Expect

Solara Active Pharma Sciences Q1 Results FY27 revenue prediction, PAT estimate, results date and 12-month analyst target.

Metric	Q1 FY27 Estimate	Q1 FY26 Actual	Context
Revenue	Rs.266-300 Cr	Rs.319 Cr	YoY revenue Q1 result preview
PAT / Profitability	Rs.4-6 Cr	Rs.11 Cr	Bottom-line Q1 prediction
Results Date	July-August 2026 (TBD)	–	Board meeting Q1 FY27 approval
12-Month Target	N/A	–	Analyst target / Uniresearch estimate

Source: Q1 FY26 actuals from company filings. Solara Active Pharma Sciences Q1 Results FY27 estimates (Q1 prediction) are Uniresearch trailing-growth projections. July 2026. Subject to change.

Key Catalysts to Watch in Solara Active Pharma Sciences Q1 Results FY27

1. Domestic Formulation Volume Growth

India’s domestic pharma market is growing at 8-10% annually led by chronic therapies and expanding healthcare access. Analysts will scrutinise management commentary on this point closely during the Solara Active Pharma Sciences Q1 Results FY27 earnings call. This is a core Q1 prediction metric watched by investors.

2. Management Guidance for FY27

Full-year FY27 revenue and EBITDA margin guidance from the Solara Active Pharma Sciences management team will be a key determinant of the stock’s reaction to Q1 Results FY27. Q1 expectations on guidance typically drive 60-70% of post-result price movement for pharmaceutical and healthcare companies.

3. Sector Macro Commentary

Management commentary on sector-specific dynamics including demand trends, input cost pressures, and competitive landscape will provide forward guidance visibility. This is one of the key Solara Active Pharma Sciences Q1 Results FY27 Q1 expectations investors will monitor for sector direction.

Key Risks for Solara Active Pharma Sciences Q1 Results FY27

USFDA regulatory warnings or Form 483 observations can disrupt US generic export revenues.
Currency volatility and global macro uncertainty can impact revenue from export-facing business segments.
Regulatory changes and compliance requirements can increase operating costs.

Track Solara Active Pharma Sciences Q1 Results FY27 Fundamentals on Univest

Solara Active Pharma Sciences Q1 FY26 Performance: Setting the Context

To understand Solara Active Pharma Sciences Q1 Results FY27 Q1 expectations, it is important to contextualise Q1 FY26 (April to June 2025) performance. Solara Active Pharma Sciences reported Q1 FY26 Revenue of Rs.319 Cr and PAT of Rs.11 Cr. This provides the year-on-year comparison base against which Solara Active Pharma Sciences Q1 Results FY27 Q1 expectations will be assessed. Any material beat or miss in the Solara Active Pharma Sciences Q1 Results FY27 Q1 result preview will likely drive meaningful stock price movement on results day.

Technical Analysis: Solara Active Pharma Sciences Share Price Levels

Solara Active Pharma Sciences Q1 Results FY27: Current market price available on NSE portal
For the latest 52-week high/low levels, track Solara Active Pharma Sciences live on the NSE portal or Univest Screener
Solara Active Pharma Sciences Q1 Results FY27 Q1 expectations: Revenue in the Rs.266-300 Cr range
The stock’s FY27 trajectory will be shaped by Solara Active Pharma Sciences Q1 Results FY27 outcome and management guidance

Download the Univest iOS App or Univest Android App to track Solara Active Pharma Sciences’s live price, charts and receive SEBI-backed research alerts.

Solara Active Pharma Sciences Share Price Target: Analyst Estimates

Short-Term Target (3 to 6 Months)

In the near term, Solara Active Pharma Sciences’s share price will be primarily driven by the Solara Active Pharma Sciences Q1 Results FY27 outcome relative to estimates. A beat on Revenue or PAT, combined with positive management guidance for FY27, could drive the stock toward the higher end of analyst expectations. Analyst Q1 prediction: a beat on Solara Active Pharma Sciences Q1 Results FY27 Revenue or PAT could drive the stock higher.

12-Month Target (Uniresearch Estimate)

The Solara Active Pharma Sciences Q1 Results FY27 12-month price target is estimated at available on the Univest research platform. This is contingent on Solara Active Pharma Sciences Q1 Results FY27 meeting Q1 expectations and FY27 guidance being constructive.

Long-Term View (FY27 to FY28)

Longer-term, the Solara Active Pharma Sciences Q1 Results FY27 Q1 result preview will anchor the FY27-FY28 outlook. Longer-term, Solara Active Pharma Sciences’s share price trajectory will depend on sector growth trends, market share dynamics, management execution quality, and India’s overall macroeconomic environment.

What to Watch on Solara Active Pharma Sciences Q1 Results FY27 Day

Solara Active Pharma Sciences Q1 Results FY27 Revenue and PAT numbers relative to Q1 Results FY27 estimates of Rs.266-300 Cr Revenue
Solara Active Pharma Sciences Q1 Results FY27 management guidance: full-year FY27 Revenue and EBITDA margin direction
Solara Active Pharma Sciences Q1 Results FY27 sector-specific operating metrics: domestic formulation volume growth and management guidance
Any dividend announcement or capital allocation guidance
Management commentary on macro headwinds including USFDA regulatory warnings or Form 483 observations can disrupt US generic export

Conclusion

Solara Active Pharma Sciences Q1 Results FY27 is one of the key Q1 result preview events for India’s pharmaceutical and healthcare sector in the July-August 2026 results season. This Solara Active Pharma Sciences Q1 Results FY27 Q1 result preview is anchored on Q1 expectations of Rs.266-300 Cr Revenue. Monitor the Univest research platform for Solara Active Pharma Sciences Q1 Results FY27 real-time commentary, Q1 predictions and Q1 expectations post the Q1 result preview declaration.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice or a stock recommendation. All estimates, analyst targets, and financial projections are based on Uniresearch trailing-growth analysis and are subject to change. Investing in stocks involves market risk. Please consult a SEBI-registered financial advisor before making any investment decision. SEBI RA INH000013776.

Frequently Asked Questions on Solara Active Pharma Sciences Q1 Results FY27

When is Solara Active Pharma Sciences Q1 FY27 results date?

Ans. The Solara Active Pharma Sciences Q1 FY27 results date has not been officially announced yet. Q1 FY27 (April to June 2026) results are typically declared in July or August 2026. Check the NSE or BSE filing portal for the exact Solara Active Pharma Sciences Q1 Results FY27 results date.

What is the Solara Active Pharma Sciences Q1 FY27 revenue estimate?

Ans. The Solara Active Pharma Sciences Q1 Results FY27 revenue prediction (Q1 FY27 estimate) based on Uniresearch trailing-growth analysis is Rs.266 to Rs.300 Cr. Actual Q1 Results FY27 revenue may differ from this Q1 prediction.

What is the Solara Active Pharma Sciences share price target?

Ans. The Solara Active Pharma Sciences Q1 Results FY27 12-month price target is available on the Univest research platform. Targets are subject to revision based on Q1 Results FY27 outcome.

Is Solara Active Pharma Sciences a good buy before Q1 FY27 results?

Ans. Investing ahead of Solara Active Pharma Sciences Q1 Results FY27 carries earnings risk. Q1 expectations and Q1 predictions vary, and quarterly results can cause sharp price moves. Assess whether Solara Active Pharma Sciences offers a good risk-reward at current levels relative to Q1 result preview scenarios. Consult a SEBI-registered financial advisor before any investment decision.

What should I watch for in Solara Active Pharma Sciences Q1 FY27 results?

Ans. Key metrics to monitor for Solara Active Pharma Sciences Q1 Results FY27 results: Revenue performance versus the Q1 prediction of Rs.266-300 Cr; PAT versus estimate; management guidance for FY27; domestic formulation volume growth progress; and management commentary on macro headwinds including USFDA regulatory warnings or Form 483 observations can disrupt US generic export.

Where can I find Solara Active Pharma Sciences Q1 FY27 results?

Ans. Solara Active Pharma Sciences Q1 Results FY27 will be available on the BSE (bseindia.com) and NSE (nseindia.com) filing portals immediately after the board meeting. For real-time analysis, expert commentary, and updated Solara Active Pharma Sciences Q1 Results FY27 Q1 prediction and Q1 expectations analysis after results are declared, download the Univest app.

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.